Nature communications · 2026
Plasma phosphorylated tau 217 and longitudinal trajectories of Aβ, tau, and cognition in cognitively unimpaired older adults.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Hyun-Sik, Anzai Juliana A U, Yau Wai-Ying Wendy, Healy Brian C, Román Viera Andrea M, Maa Courtney, Kirn Dylan, Properzi Michael J, Bellier Jean-Pierre, Schultz Aaron P, Farrell Michelle E, Jacobs Heidi I L, Buckley Rachel F, Papp Kathryn V, Marshall Gad A, Amariglio Rebecca E, Rentz Dorene M, Liu Lei, Selkoe Dennis J, Verghese Philip B, Braunstein Joel B, Johnson Keith A, Sperling Reisa A, Chhatwal Jasmeer P
Аннотация
Plasma phosphorylated tau 217 (pTau217) is an excellent biomarker of Alzheimer's disease (AD) pathology, but it remains uncertain whether pTau217 can predict amyloid-β (Aβ) and tau accumulation prior to Aβ positron emission tomography (PET) positivity. Here, we leverage data from a well-characterized prospective cohort of cognitively unimpaired older adults to examine mass spectrometry-based plasma %pTau217 (pTau217/non-phosphorylated-Tau217×100) relative to changes in Aβ/tau PET and cognition. A higher baseline %pTau217 was associated with faster Aβ and tau accumulation on PET, which then led to greater cognitive decline. Among individuals Aβ PET-negative at baseline, higher %pTau217 levels presaged increases in Aβ and tau PET signals. Together, our results suggest that very low %pTau217 in cognitively unimpaired older adults is associated with a minimal risk of AD pathology accumulation and cognitive decline.